(redirected from Chronic Myeloproliferative Disorder)
Also found in: Medical.
CMPDCharlotte-Mecklenburg Police Department (Charlotte, NC)
CMPDChronic Myeloproliferative Disorder
CMPDCrisis Management and Planning Directorate (EU)
CMPDCampomelic Dysplasia
CMPDComputational and Mathematical Population Dynamics (conference)
CMPDCustom Microcomputer Program Design
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
The 2001 World Health Organization (WHO) and the updated European Clinical and Pathological (ECP) criteria for the diagnosis, classification and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders. Sem Thromb Hemostas 2006;32:307-340.
Prevalence ofJAK2 V619F mutation in Indian patients with chronic myeloproliferative disorders. Indian J Med Res 2010; 132: 423-27.
However, at least in patients with idiopathic myelofibrosis and other chronic myeloproliferative disorders, an alternative pathogenesis has been proposed.
Chronic myeloproliferative disorders (CMPDs) are clonal haematopoietic stem cell disorders and include the BCR-ABL negative CMPDs like polycythemia vera (PV), essential thrombocythemia (ET), idiopathic myelofibrosis (IMF) and chronic eosinophilic leukaemia (CEL) (1,2).
Philadelphia-negative chronic myeloproliferative disorders (CMDs) are characterized by clonal proliferation of hematopoietic progenitor cells in the bone marrow and by extramedullary hematopoiesis associated with increased [CD34.sup.+] circulating cells (10-12).
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood.
To establish a diagnosis of ET, reactive causes of thrombocytosis should be absent and other chronic myeloproliferative disorders should be ruled out (1).
In the absence of pathognomonic markers, the diagnosis of the two chronic myeloproliferative disorders polycythemia vera (PV) and essential thrombocythemia (ET) has relied on a set of clinical and laboratory criteria (1-5).
Full browser ?